Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMBRIA-1: camizestrant versus standard endocrine therapy as extended adjuvant treatment for ER-positive/HER2-negative early breast cancer
MOH_2023-07-23_012774Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Started Jul 2023; status: recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2023-07-23_012774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-23_012774.